MedTrace Logo

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

NCT01519492 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2012-08-07

No results posted yet for this study

Summary

The purpose of the study is to determine the safety, tolerability and effectiveness of AFN-12520000 for in the treatment of Staphylococcal infections of the skin.

Conditions

  • Skin and Subcutaneous Tissue Bacterial Infections
  • Wound Infection
  • Cutaneous Abscess
  • Burn Infection
  • Cellulitis

Interventions

DRUG

AFN-12520000

Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg

Sponsors & Collaborators

  • Affinium Pharmaceuticals, Ltd

    lead INDUSTRY

Principal Investigators

  • Barry Hafkin, MD · Affinium Pharmaceuticals, Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01519492 on ClinicalTrials.gov